Maffrand JP - Search Results

1

Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.

Gully D, Fréhel D, Marcy C, Spinazzé A, Lespy L, Neliat G, Maffrand JP, Le Fur G. Gully D, et al. Among authors: maffrand jp. Eur J Pharmacol. 1993 Feb 23;232(1):13-9. doi: 10.1016/0014-2999(93)90722-t. Eur J Pharmacol. 1993. PMID: 7681406

2

Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.

Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G. Herbert JM, et al. Among authors: maffrand jp. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51. J Pharmacol Exp Ther. 1991. PMID: 1656029

3

Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice.

Herbert JM, Lespy L, Maffrand JP. Herbert JM, et al. Among authors: maffrand jp. Eur J Pharmacol. 1991 Dec 3;205(3):271-6. doi: 10.1016/0014-2999(91)90909-a. Eur J Pharmacol. 1991. PMID: 1817964

4

Effects of SR 49059, a non-peptide antagonist of vasopressin V1a receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits.

Serradeil-Le Gal C, Villanova G, Boutin M, Maffrand JP, Le Fur G. Serradeil-Le Gal C, et al. Among authors: maffrand jp. Fundam Clin Pharmacol. 1995;9(1):17-24. doi: 10.1111/j.1472-8206.1995.tb00260.x. Fundam Clin Pharmacol. 1995. PMID: 7768483

5

Neuropharmacological profile of non-peptide neurotensin antagonists.

Gully D, Jeanjean F, Poncelet M, Steinberg R, Soubrié P, Le Fur G, Maffrand JP. Gully D, et al. Among authors: maffrand jp. Fundam Clin Pharmacol. 1995;9(6):513-21. doi: 10.1111/j.1472-8206.1995.tb00528.x. Fundam Clin Pharmacol. 1995. PMID: 8808171 Review.

6

Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist.

Emonds-Alt X, Advenier C, Cognon C, Croci T, Daoui S, Ducoux JP, Landi M, Naline E, Neliat G, Poncelet M, Proietto V, Van Broeck D, Vilain P, Soubrié P, Le Fur G, Maffrand JP, Brelière JC. Emonds-Alt X, et al. Among authors: maffrand jp. Neuropeptides. 1997 Oct;31(5):449-58. doi: 10.1016/s0143-4179(97)90039-1. Neuropeptides. 1997. PMID: 9413022

7

Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.

Bernat A, Herbert JM, Salel V, Lespy L, Maffrand JP. Bernat A, et al. Among authors: maffrand jp. J Lipid Mediat. 1992 Feb;5(1):41-8. J Lipid Mediat. 1992. PMID: 1391738

8

Biochemical and pharmacological activities of SR 26831, a potent and selective elastase inhibitor.

Herbert JM, Frehel D, Rosso MP, Seban E, Castet C, Pepin O, Maffrand JP, Le Fur G. Herbert JM, et al. Among authors: maffrand jp. J Pharmacol Exp Ther. 1992 Feb;260(2):809-16. J Pharmacol Exp Ther. 1992. PMID: 1738126

9

[Neurotensin receptor antagonists and therapeutical perspectives].

Gully D, Maffrand JP, Soubrié P, Rostène W, Kitabgi P, Le Fur G. Gully D, et al. Among authors: maffrand jp. Therapie. 1995 Jan-Feb;50(1):5-7. Therapie. 1995. PMID: 7754478 Review. French.

10

Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.

Serradeil-Le Gal C, Herbert JM, Delisee C, Schaeffer P, Raufaste D, Garcia C, Dol F, Marty E, Maffrand JP, Le Fur G. Serradeil-Le Gal C, et al. Among authors: maffrand jp. Am J Physiol. 1995 Jan;268(1 Pt 2):H404-10. doi: 10.1152/ajpheart.1995.268.1.H404. Am J Physiol. 1995. PMID: 7840290

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters